Evidence map›Paper›PMID 36213361›Full record

ArticleJACC. CardioOncology2022

Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients With Active Cancer.

Adam S Potter, Ashley Patel, Muzamil Khawaja, Christopher Chen, Henry Zheng, Jessica Kaczmarek, Feng Gao, Kaveh Karimzad, Juhee Song, Efstratios Koutroumpakis and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Adam S PotterDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ashley PatelDepartment of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
Muzamil KhawajaDepartment of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
Christopher ChenDepartment of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
Henry ZhengDepartment of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
Jessica KaczmarekDepartment of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
Feng GaoDepartment of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
Kaveh KarimzadDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Juhee SongDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Efstratios KoutroumpakisDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shaden KhalafDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cezar IliescuDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anita DeswalDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nicolas L PalaskasDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The choice of anticoagulant agent for patients with nonvalvular atrial fibrillation (NVAF) in the setting of active cancer has not been well studied. Objectives: The aim of this study was to compare the rates of cerebrovascular accident (CVA), gastrointestinal bleeding (GIB), and intracranial hemorrhage (ICH) in patients treated with direct oral anticoagulant agents (DOACs) compared with warfarin for NVAF in patients with active cancer. Methods: This was a retrospective electronic medical record review of eligible patients treated at a cancer hospital. The outcome events were CVA; GIB; ICH; the composite of GIB, CVA, or ICH; and overall mortality. Propensity score matching (1:1) was conducted to select comparable patients receiving warfarin vs DOACs. Fine-Gray models were fitted for each outcome event. Results: The study cohort included 1,133 patients (mean age 72 ± 8.8 years, 42% women), of whom 74% received DOACs (57% received apixaban). After propensity score matching, 195 patients were included in each anticoagulant agent group. When comparing warfarin with DOACs, there were similar risks for CVA (subdistribution HR: 0.738; 95% CI: 0.334-1.629); ICH (subdistribution HR: 0.295; 95% CI: 0.032-2.709); GIB (subdistribution HR: 1.819; 95% CI: 0.774-4.277); and the composite of GIB, CVA, or ICH (subdistribution HR: 1.151; 95% CI: 0.645-2.054). Conclusions: Patients with active cancer had similar risks for CVA, ICH, and GIB when treated with DOACs compared with warfarin for NVAF.

Indexed as

bleedingcancerCVA, cerebrovascular accidentDOACDOAC, direct oral anticoagulant agentGIB, gastrointestinal bleedingICH, intracranial hemorrhageLMWH, low–molecular weight heparinnonvalvular atrial fibrillationNVAF, nonvalvular atrial fibrillationstrokeTIA, transient ischemic attackvitamin K antagonistVKA, vitamin K antagonistVTE, venous thromboembolismwarfarin

Identifiers

PMID36213361
PMCPMC9537073
OpenAlexW4296514381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.